Nonclinical Questions? When to Request an FDA Meeting
Should You Meet With FDA About Your Nonclinical Safety [...]
FDA INTERACT Meetings: A Guide for Emerging Biotechs
How Emerging Biotechs Use FDA INTERACT Meetings to Avoid Costly [...]
Facet Life Sciences: Certified Great Place to Work®, Again
Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
Sometimes a Second Opinion Is Worth Millions
Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
Target Product Profile for Emerging Biotech: Strategic Asset or Expensive Distraction?
Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
Facet Life Sciences Evolves Leadership Structure to Strengthen Regulatory Pathmaking Solutions & Deepen Partnership Value
Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
Facet’s Dana Blue Returns to AMWA Regulatory Writing Subcommittee for 2026
Shaping The Future of Regulatory Writing Education Facet Life Sciences [...]
Why Separating Regulatory and Commercial Strategy Can Kill an Otherwise Promising Biotech
For many small biotech teams, regulatory and commercial strategies are [...]
Behind the Scenes of a Productive Nonclinical Type C Meeting Strategy
How a novel pediatric gene therapy developer leveraged regulatory gap [...]
Leveraging Breakthrough Therapy Designation (BTD) for Gene Therapy Development
What every developer should know to maximize BTD value by [...]
gET sOCIAL